EDGEMOND JAMES sold $1.5M of UTHR
EDGEMOND JAMES (CFO AND TREASURER) sold 2,749 shares of UNITED THERAPEUTICS Corp (UTHR) at $548.04 ($1.51M total) on 2026-06-04 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
Traders may treat the disclosure as a mild sentiment input rather than a standalone fundamental driver, given the pre-arranged nature.
Market read
A routine 10b5-1 insider sale for UTHR disclosed after-hours/filing time; expected impact is limited.
What to watch
The filing does not reveal the insider’s total holdings trajectory beyond the post-transaction balance, nor whether other sales occurred under separate plans.
Background
SEC Form 4 reports insider transactions; this one is an officer (CFO & Treasurer) open-market sale under a pre-arranged 10b5-1 plan.
Ticker impact
United Therapeutics CFO sold 2,749 shares in an open-market transaction worth about $1.51M, disclosed via SEC Form 4.
Likely limited near-term impact; any effect is more about sentiment/positioning than fundamentals.
The filing is a routine Form 4 datapoint (officer sale) with a stated pre-arranged 10b5-1 plan, which typically dampens interpretive value.
Market effects
Minimal—this is company-specific insider activity without sector-wide regulatory/drug/earnings implications.
Minimal—no cross-market or macro linkage indicated.
Minimal—no international transaction or guidance affecting global operations mentioned.
Counterpoint
Even with a 10b5-1 plan, repeated insider selling can still coincide with internal risk management or diversification needs.
Key entities
- issuerUnited Therapeutics Corp
Subject of the Form 4 insider transaction; CFO & Treasurer sold shares on June 4, disclosed June 5.
- insiderEDGEMOND JAMES
CFO and Treasurer who executed the open-market sale under a 10b5-1 plan.
